ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 001,80
-0,48%
Dow Jones
38 798,99
-0,22%
DAX
18 557,27
-0,48%
Brent Oil
79,395
0,00%
Bitcoin
69 389,36
0,08%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. 4D Molecular Therapeutics Inc (FDMT)

  7. 4D Molecular Therapeutics Inc (FDMT) Actualités

FDMT

4D Molecular Therapeutics (FDMT)

4D Molecular Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:FDMT
DateHeureSourceTitreSymboleSociété
07/06/202423h07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:FDMT4D Molecular Therapeutics Inc
07/06/202423h04Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:FDMT4D Molecular Therapeutics Inc
06/06/202413h30GlobeNewswire Inc.4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Modulator-Ineligible/-Intolerant Cystic Fibrosis at 47th European Cystic Fibrosis ConferenceNASDAQ:FDMT4D Molecular Therapeutics Inc
04/06/202414h00GlobeNewswire Inc.4DMT Announces Presentations at Clinical Trials at the Summit 2024 MeetingNASDAQ:FDMT4D Molecular Therapeutics Inc
03/06/202414h00GlobeNewswire Inc.4DMT to Participate in Upcoming Investor ConferencesNASDAQ:FDMT4D Molecular Therapeutics Inc
30/05/202414h00GlobeNewswire Inc.4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 47ᵗʰ European Cystic Fibrosis ConferenceNASDAQ:FDMT4D Molecular Therapeutics Inc
24/05/202401h12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FDMT4D Molecular Therapeutics Inc
09/05/202422h05GlobeNewswire Inc.4DMT Reports First Quarter 2024 Financial Results and Operational HighlightsNASDAQ:FDMT4D Molecular Therapeutics Inc
07/05/202414h00GlobeNewswire Inc.4DMT to Participate in Upcoming Investor ConferenceNASDAQ:FDMT4D Molecular Therapeutics Inc
01/05/202414h00GlobeNewswire Inc.4DMT Announces Presentations at ARVO 2024 Annual MeetingNASDAQ:FDMT4D Molecular Therapeutics Inc
28/03/202413h00GlobeNewswire Inc.4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic FibrosisNASDAQ:FDMT4D Molecular Therapeutics Inc
29/02/202423h15Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:FDMT4D Molecular Therapeutics Inc
29/02/202422h05GlobeNewswire Inc.4DMT Reports Full Year 2023 Financial Results and Operational HighlightsNASDAQ:FDMT4D Molecular Therapeutics Inc
15/02/202402h51Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:FDMT4D Molecular Therapeutics Inc
12/02/202414h00GlobeNewswire Inc.4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium™ 2024NASDAQ:FDMT4D Molecular Therapeutics Inc
08/02/202422h50Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:FDMT4D Molecular Therapeutics Inc
08/02/202401h42Edgar (US Regulatory)Form 3/A - Initial statement of beneficial ownership of securities: [Amend]NASDAQ:FDMT4D Molecular Therapeutics Inc
07/02/202405h27GlobeNewswire Inc.4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common StockNASDAQ:FDMT4D Molecular Therapeutics Inc
05/02/202422h35Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:FDMT4D Molecular Therapeutics Inc
05/02/202422h05GlobeNewswire Inc.4D Molecular Therapeutics Announces Proposed Public Offering of Common StockNASDAQ:FDMT4D Molecular Therapeutics Inc
03/02/202423h00GlobeNewswire Inc.4DMT Presents Positive Interim Data from Randomized Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMDNASDAQ:FDMT4D Molecular Therapeutics Inc
29/01/202414h00GlobeNewswire Inc.4DMT to Host Corporate Webcast to Discuss Interim Data from Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 in Wet AMD Patients with Severe Disease Activity & High Treatment BurdenNASDAQ:FDMT4D Molecular Therapeutics Inc
23/01/202414h00GlobeNewswire Inc.4DMT Receives Rare Pediatric Disease Designation from FDA for Aerosolized 4D-710 for Treatment of Cystic Fibrosis Lung DiseaseNASDAQ:FDMT4D Molecular Therapeutics Inc
04/01/202414h00GlobeNewswire Inc.4DMT Highlights Recent Clinical Pipeline Progress, Near-Term Milestones and Organizational UpdatesNASDAQ:FDMT4D Molecular Therapeutics Inc
03/01/202414h01GlobeNewswire Inc.4DMT and Arbor Biotechnologies Establish Partnership to Co-Develop and Co-Commercialize Next-Generation Genetic Medicines for CNS DiseasesNASDAQ:FDMT4D Molecular Therapeutics Inc
21/12/202318h31Dow Jones News4D Molecular Shares Rise on FDA Designation for Wet AMD DrugNASDAQ:FDMT4D Molecular Therapeutics Inc
21/12/202314h00GlobeNewswire Inc.4DMT Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for 4D-150 Genetic Medicine for Intravitreal Treatment of Wet AMD, the First RMAT Designation in Wet AMDNASDAQ:FDMT4D Molecular Therapeutics Inc
04/12/202314h00GlobeNewswire Inc.4DMT to Present Interim 24 Week Data from Randomized Phase 2 PRISM Clinical Trial of 4D-150 in High Treatment Need Wet AMD Patients at Angiogenesis, Exudation, and Degeneration 2024 ConferenceNASDAQ:FDMT4D Molecular Therapeutics Inc
09/11/202322h19GlobeNewswire Inc.4DMT Reports Third Quarter 2023 Financial Results and Operational HighlightsNASDAQ:FDMT4D Molecular Therapeutics Inc
01/11/202321h00GlobeNewswire Inc.4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Cystic Fibrosis at 2023 NACFCNASDAQ:FDMT4D Molecular Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:FDMT

Dernières Valeurs Consultées

UNSW
LKRETH
Polkalokr
ASX
HFRJOZ
LATK
PETSUSDT
MicroPets
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés